Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 3, 2008, Pages 539-542

  Lamaris, G A ^a   Ben Ami, R ^a   Lewis, R E ^a,b   Kontoyiannis, D P ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Drosophila melanogaster; Fungal infections; Triazoles

Indexed keywords

GLUCOSE; POSACONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONIDIUM; CONTROLLED STUDY; CULTURE MEDIUM; DROSOPHILA MELANOGASTER; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG TISSUE LEVEL; FUNGAL VIRULENCE; FUNGUS CULTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PROTECTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; YEAST;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; PYRIMIDINES; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTORS; TRIAZOLES; VIRULENCE;

EID: 49649120958     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn224     Document Type: Article

References (12)

1. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56: 5-11.
2. Comely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
3. Wingard JR, Carter SL, Walsh TJ et al. Results of a randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Abstract 163. Blood 2007; 11: 55a-6a, Abstract 163.
4. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
5. Lionakis MS, Lewis RE, May GS et al. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis 2005; 191: 1188-95.
6. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46: 556-7.
7. Chamilos G, Lionakis MS, Lewis RE et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis 2006; 193: 1014-22.
8. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium Forming Filamentous Fungi: Approved Standard M38-A. NCCLS, Wayne, PA, USA, 2002.
9. Lamaris GA, Lewis RE, Chamilos G et al. Voriconazole pre-exposed Rhizopus oryzae has increased virulence in experimental Zygomycosis in flies and mice. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract B-1449, p. 60. American Society for Microbiology, Washington, DC, USA.
10. Liu W, Lionakis MS, Lewis RE et al. Attenuation of itraconazole fungicidal activity following preexposure of Aspergillus fumigatus to fluconazole. Antimicrob Agents Chemother 2003; 47: 3592-7.
11. Kontoyiannis DP, Lewis RE, Lionakis MS et al. Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: Evidence of enhanced in vitro activity. Diagn Microbiol Infect Dis 2003; 47: 415-9.
12. Lewis RE, Prince RA, Chi J et al. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 46: 3208-14.